Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development

References

• Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts; 2021.
   Google Scholar
• Centres for Disease Control and Prevention. Overdose death rates involving opioids, by type, United States, 1999-2019. National Center Injury Prev Control. 2021;2.
   Google Scholar
• O’Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the field: opioid-involved overdose deaths with fentanyl or fentanyl analogs detected — 28 states and the District of Columbia, July 2016–december 2018. MMWR Morb Mortal Wkly Rep. 2020;69(10):1–15. doi:10.15585/mmwr.mm6910a4.
   PubMed Web of Science ®Google Scholar
• Shover CL, Falasinnu TO, Dwyer CL, Santos NB, Cunningham NJ, Freedman RB, Vest NA, Humphreys K. Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314.
   PubMed Web of Science ®Google Scholar
• Krotulski AJ, Chapman BP, Marks SJ, Ontiveros, ST, Devin-Holcombe, K, Fogarty, MF, Trieu, H, Logan, BK, Merchant, RC, Babu, KM. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose. Clin Toxicol. 2022;60(2):197–204. doi:10.1080/15563650.2021.1948558.
   PubMed Web of Science ®Google Scholar
• Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134:121–32. doi:10.1016/j.neuropharm.2017.10.016.
   PubMed Web of Science ®Google Scholar
• Baumgartner JC, Radley DC. The drug overdose toll in 2020 and near-term actions for addressing it. The Commonwealth Fund; 2021.
   Google Scholar
• Martin WR. Drugs five years later: naloxone. Ann Intern Med. 1976;85(6):765. doi:10.7326/0003-4819-85-6-765.
   PubMedGoogle Scholar
• Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88. doi:10.1177/2042098617744161.
   PubMed Web of Science ®Google Scholar
• Ahonen J, Olkkola KT, Hynynen M, Seppälä T, Ikävalko H, Remmerie B, Salmenperä M. Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery†. Br J Anaesth. 2000;85(4):533–40. doi:10.1093/bja/85.4.533.
   PubMed Web of Science ®Google Scholar
• Clarke SFJ, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emergency Med J. 2005;22(9):612–16. doi:10.1136/emj.2003.009613.
   PubMed Web of Science ®Google Scholar
• Moss RB, Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. Subst Abuse Treat Prev Policy. 2019;14(1):6. doi:10.1186/s13011-019-0195-4.
   PubMed Web of Science ®Google Scholar
• Torralva R, Janowsky A. Noradrenergic mechanisms in Fentanyl-Mediated rapid death explain failure of naloxone in the opioid crisis. J Pharmacol Exp Ther. 2019;371(2):453–75. doi:10.1124/jpet.119.258566.
   PubMed Web of Science ®Google Scholar
• Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673–80. doi:10.1172/JCI106279.
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discovery Dev. 2007;10:84–96.
   PubMed Web of Science ®Google Scholar
• Roiko SA, Harris AC, LeSage MG, Keyler DE, Pentel PR. Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol Biochem Behav. 2009;93(2):105–11. doi:10.1016/j.pbb.2009.04.011.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, King SJ, Baruffaldi F, Saykao A, Hamid FA, Winston S, LeSage MG, Pentel PR, Pravetoni M. Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. Neuropharmacology. 2021;195:108653. doi:10.1016/j.neuropharm.2021.108653.
   PubMed Web of Science ®Google Scholar
• Robinson C, Gradinati V, Hamid F, Baehr C, Crouse B, Averick S, Kovaliov M, Harris D, Runyon S, Baruffaldi F, et al. Therapeutic and prophylactic vaccines to counteract Fentanyl use disorders and toxicity. J Med Chem. 2020;63(23):14647–67. doi:10.1021/acs.jmedchem.0c01042.
   PubMed Web of Science ®Google Scholar
• Baehr C, Kelcher AH, Khaimraj A, Reed DE, Pandit SG, AuCoin D, Averick S, Pravetoni M. Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats. J Pharmacol Exp Ther. 2020;375(3):469–77. doi:10.1124/jpet.120.000124.
   PubMed Web of Science ®Google Scholar
• Ban B, Barrientos RC, Oertel T, Komla E, Whalen C, Sopko M, You Y, Banerjee P, Sulima A, Jacobson AE, et al. Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice. MAbs. 2021;13(1). doi:10.1080/19420862.2021.1991552.
   Web of Science ®Google Scholar
• Smith LC, Bremer PT, Hwang CS, Zhou B, Ellis B, Hixon MS, Janda KD. Monoclonal antibodies for combating synthetic opioid intoxication. J Am Chem Soc. 2019;141(26):10489–503. doi:10.1021/jacs.9b04872.
   PubMed Web of Science ®Google Scholar
• Wetzel HN, Webster RP, Saeed FO, Kirley TL, Ball WJ, Norman AB. Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate. Biochem Biophys Res Commun. 2017;487(3):690–94. doi:10.1016/j.bbrc.2017.04.117.
   PubMed Web of Science ®Google Scholar
• Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol. 2006;6(6):968–77. doi:10.1016/j.intimp.2006.01.008.
   PubMed Web of Science ®Google Scholar
• Stevens MW, Tawney RL, West CM, et al. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs. 2014;6(2):547–55. doi:10.4161/mabs.27620.
   PubMed Web of Science ®Google Scholar
• Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014;6(6):1649–56. doi:10.4161/19420862.2014.976431.
   PubMed Web of Science ®Google Scholar
• Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol. 1994;1(4):365–72. doi:10.1128/cdli.1.4.365-372.1994.
   PubMedGoogle Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10. doi:10.1016/j.ymeth.2005.01.001.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge R. The immunogenicity of humanized and fully human antibodies. Mabs. 2010;2(3):256–65. doi:10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the European Union or the United States. 2022. http://www.antibodysociety.org/resources/approved-antibodies.
   Google Scholar
• Meyer L, López T, Espinosa R, Arias CF, Vollmers C, DuBois RM. A simplified workflow for monoclonal antibody sequencing. PLoS ONE. 2019;14(6):e0218717. doi:10.1371/journal.pone.0218717.
   PubMed Web of Science ®Google Scholar
• Baehr C, Robinson C, Kassick A, Jahan R, Gradinati V, Averick SE, Runyon SP, Pravetoni M. Preclinical efficacy and selectivity of vaccines targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in rats. ACS Omega. 2022;7(19):16584–92. doi:10.1021/acsomega.2c00820.
   PubMed Web of Science ®Google Scholar
• Crouse B, Wu MM, Gradinati V, Kassick AJ, Song D, Jahan R, Averick S, Runyon S, Comer SD, Pravetoni M, et al. Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to Carfentanil, Fentanyl, and their mixtures in rats. ACS Pharmacol Transl Sci. 2022;5(5):331–43. doi:10.1021/acsptsci.1c00260.
   PubMedGoogle Scholar
• Ehrenmann F, Lefranc M-P. Imgt/domaingapalign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF). Cold Spring Harb Protoc. 2011;2011(6):737–49. doi:10.1101/pdb.prot5636.
   PubMedGoogle Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116(10):4025–30. doi:10.1073/pnas.1810576116.
   PubMed Web of Science ®Google Scholar
• Swindells MB, Porter CT, Couch M, Hurst J, Abhinandan KR, Nielsen JH, Macindoe G, Hetherington J, Martin ACR. abYsis: integrated antibody sequence and structure—management, analysis, and prediction. J Mol Biol. 2017;429(3):356–64. doi:10.1016/j.jmb.2016.08.019.
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Deamidation of human proteins. Proc Nat Acad Sci. 2001;98(22):12409–13. doi:10.1073/pnas.221463198.
   PubMed Web of Science ®Google Scholar
• Qiu H, Wei R, Jaworski J, Boudanova E, Hughes H, VanPatten S, Lund A, Day J, Zhou Y, McSherry T, et al. Engineering an anti-CD52 antibody for enhanced deamidation stability. Mabs. 2019;11(7):1266–75. doi:10.1080/19420862.2019.1631117.
   PubMed Web of Science ®Google Scholar
• Cacia J, Keck R, Presta LG, Frenz J. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. 1996;35(6):1897-903. doi:10.1021/bi951526c.
   Google Scholar
• Patel CN, Bauer SP, Davies J, Durbin JD, Shiyanova TL, Zhang K, Tang JX. N+1 engineering of an aspartate isomerization hotspot in the complementarity-determining region of a monoclonal antibody. J Pharm Sci. 2016;105(2):512–18. doi:10.1016/S0022-3549(15)00185-9.
   PubMed Web of Science ®Google Scholar
• Baehr CA, Wu MM, Pandit SG, Arias-Umana J, AuCoin D, Pravetoni M. Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre- and postexposure models of fentanyl toxicity. J Pharmacol Exp Ther. 2022;381(2):129–36. doi:10.1124/jpet.121.001048.
   PubMed Web of Science ®Google Scholar
• Safdari Y, Farajnia S, Asgharzadeh M, Khalili M. Antibody humanization methods - a review and update. Biotechnol Genet Eng Rev. 2013;29(2):175–86. doi:10.1080/02648725.2013.801235.
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J. The immunogenicity of biologic therapies. Curr Probl Dermatol. 2018;53:37–48. doi:10.1159/000478077.
   PubMedGoogle Scholar
• Lefranc M-P. IMGT Unique Numbering. The Immunologist. 1999;7:132–36.
   Google Scholar
• Kabat EA, Te Wu T, Perry HM, Foeller C, Gottesman KS. Sequences of proteins of immunological interest. Darby: DIANE Publishing; 1992.
   Google Scholar
• Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol. 1997;273(4):927–48. doi:10.1006/jmbi.1997.1354.
   PubMed Web of Science ®Google Scholar
• Martin AC, Cheetham JC, Rees AR. Modeling antibody hypervariable loops: a combined algorithm. Proc Natl Acad Sci U S A. 1989;86(23):9268–72. doi:10.1073/pnas.86.23.9268.
   PubMed Web of Science ®Google Scholar
• Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure. Nucleic Acids Res. 2012;40(W1):W521–W524. doi:10.1093/nar/gks480.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. doi:10.1080/19420862.2018.1553476.
   PubMed Web of Science ®Google Scholar
• Fekete S, Beck A, Veuthey JL, Guillarme D. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal. 2014;101:161–73. doi:10.1016/j.jpba.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Haverick M, Mengisen S, Shameem M, Ambrogelly A. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. Mabs. 2014;6(4):852–58. doi:10.4161/mabs.28693.
   PubMed Web of Science ®Google Scholar
• Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P, et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen. 2001;6(6):429–40. doi:10.1177/108705710100600609.
   PubMed Web of Science ®Google Scholar
• Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc. 2009;131(11):3794–95. doi:10.1021/ja8049063.
   PubMed Web of Science ®Google Scholar
• Ma H, Ó’fágáin C, O’Kennedy R. Antibody stability: a key to performance - analysis, influences and improvement. Biochimie. 2020;177:213–25. doi:10.1016/j.biochi.2020.08.019.
   PubMed Web of Science ®Google Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. Mabs. 2020;12(1). doi:10.1080/19420862.2020.1743053.
   Web of Science ®Google Scholar
• Goyon A, D’Atri V, Colas O, Fekete S, Beck A, Guillarme D. Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation. J Chromatogr B. 2017;1065–1066:35–43. doi:10.1016/j.jchromb.2017.09.027.
   PubMed Web of Science ®Google Scholar
• Estep P, Caffry I, Yu Y, Sun T, Cao Y, Lynaugh H, Jain T, Vásquez M, Tessier PM, Xu Y, et al. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies. MAbs. 2015;7(3):553–61. doi:10.1080/19420862.2015.1016694.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1–26. doi:10.1002/jps.20727.
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Semple A, James JK, Cheung JK, Shameem M. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability. MAbs. 2016;8(6):1088–97. doi:10.1080/19420862.2016.1189048.
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun. 2007;355(3):751–57. doi:10.1016/j.bbrc.2007.02.042.
   PubMed Web of Science ®Google Scholar
• Kirley TL, Norman AB, Wetzel HN. A novel differential scanning fluorimetry analysis of a humanized anti-cocaine mAb and its ligand binding characteristics. J Immunol Methods. 2020;476:112676. doi:10.1016/j.jim.2019.112676.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol. 2020;177(2):254–65. doi:10.1111/bph.14860.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Dahan A, Ann LeQuang J, Raffa RB. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. J Clin Pharm Ther. 2021;46(6):1501–04. doi:10.1111/jcpt.13462.
   PubMed Web of Science ®Google Scholar
• Gervais D. Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. J Chem Technol Biotechnol. 2016;91(3):569–75. doi:10.1002/jctb.4850.
   Web of Science ®Google Scholar
• Zhou K, Cao X, Bautista J, Chen Z, Hershey N, Ludwig R, Tao L, Zeng M, Das TK. Structure-function assessment and high-throughput quantification of site-specific aspartate isomerization in monoclonal antibody using a novel analytical tool kit. J Pharm Sci. 2020;109(1):422–28. doi:10.1016/j.xphs.2019.08.018.
   PubMed Web of Science ®Google Scholar
• Yang R, Jain T, Lynaugh H, Nobrega RP, Lu X, Boland T, Burnina I, Sun T, Caffry I, Brown M, et al. Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies. Mabs. 2017;9(4):646–53. doi:10.1080/19420862.2017.1290753.
   PubMed Web of Science ®Google Scholar
• Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, Sivasubramanian A, Vásquez M, Xu Y. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019;11(1):45–57. doi:10.1080/19420862.2018.1548233.
   PubMed Web of Science ®Google Scholar
• Nowak C, Cheung JK, Dellatore SM, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, et al. Forced degradation of recombinant monoclonal antibodies: a practical guide. Mabs. 2017;9(8):1217–30. doi:10.1080/19420862.2017.1368602.
   PubMed Web of Science ®Google Scholar
• Wang SS, Yan Y, Ho K. US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antib Ther. 2021;4(4):262–73. doi:10.1093/abt/tbab027.
   PubMedGoogle Scholar
• Mathaes R, Koulov A, Joerg S, Mahler HC. Subcutaneous injection volume of biopharmaceuticals-pushing the boundaries. J Pharm Sci. 2016;105(8):2255–59. doi:10.1016/j.xphs.2016.05.029.
   PubMed Web of Science ®Google Scholar
• Ogston-Tuck S. Intramuscular injection technique: an evidence-based approach. Nurs Stand. 2014;29(4):52–59. doi:10.7748/ns.29.4.52.e9183.
   PubMedGoogle Scholar
• Dear BJ, Hung JJ, Laber JR, Wilks LR, Sharma A, Truskett TM, Johnston KP. Enhancing stability and reducing viscosity of a monoclonal antibody with cosolutes by weakening protein-protein interactions. J Pharm Sci. 2019;108(8):2517–26. doi:10.1016/j.xphs.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Shahfar H, Du Q, Parupudi A, Shan L, Esfandiary R, Roberts CJ. Electrostatically driven protein–protein interactions: quantitative prediction of second osmotic virial coefficients to aid antibody design. J Phys Chem Lett. 2022;13(5):1366–72. doi:10.1021/acs.jpclett.1c03669.
   PubMed Web of Science ®Google Scholar
• Calero-Rubio C, Saluja A, Sahin E, Roberts CJ. Predicting high-concentration interactions of monoclonal antibody solutions: comparison of theoretical approaches for strongly attractive versus repulsive conditions. J Phys Chem B. 2019;123(27):5709–20. doi:10.1021/acs.jpcb.9b03779.
   PubMed Web of Science ®Google Scholar
• Strickley RG, Lambert WJ. A review of formulations of commercially available antibodies. J Pharm Sci. 2021;110(7):2590–608.e56. doi:10.1016/j.xphs.2021.03.017.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10(JUN):1296. doi:10.3389/fimmu.2019.01296.
   PubMedGoogle Scholar
• Hay CE, Ewing LE, Hambuchen MD, et al. The development and characterization of an scFv-Fc fusion–based gene therapy to reduce the psychostimulant effects of methamphetamine abuse. J Pharmacol Exp Ther. 2020;374(1):16–23. doi:10.1124/jpet.119.261180.
   PubMed Web of Science ®Google Scholar
• Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. Natl Vital Stat Rep. 2018;67:1–14.
   PubMedGoogle Scholar
• Lockwood TLE, Huynh P, Richard A, Sightes E, Bailey K, Ray B, Lieberman M. Community overdose surveillance: comparing substances collected from the death scene investigation to toxicology results. Drug Alcohol Depend. 2021;224:108722. doi:10.1016/j.drugalcdep.2021.108722.
   PubMed Web of Science ®Google Scholar